87597-21-5

Usage

Uses

Used in Pharmaceutical Industry:
6,8-Dibromo-imidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure and functional groups make it a valuable building block in the development of new drugs, potentially contributing to the treatment of various diseases and conditions.
Used in Chemical Research:
6,8-Dibromo-imidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester is used as a research compound in the field of organic chemistry. It serves as a model for studying the reactivity and properties of similar molecules, which can lead to a better understanding of chemical reactions and the development of new synthetic methods.
Used in Industrial Chemical Processes:
6,8-Dibromo-imidazo[1,2-a]pyrazine-2-carboxylic acid ethyl ester is used as a reactant or catalyst in certain industrial chemical processes. Its specific functional groups may be utilized to facilitate reactions or improve the efficiency of production, making it a valuable component in the synthesis of various industrial chemicals.

Upstream product

• 65868-37-3 ethyl 2-oxo-3-chloropropionate 
• 24241-18-7 2-amino-3,5-dibromopyrazine 
• 70-23-5 ethyl Bromopyruvate 

Downstream Products

• 1382451-79-7 N-cyclopropyl-4-[6,8-dibromo-2-(hydroxymethyl)imidazo[1,2-a]pyrazin-3-yl]benzamide 
• 1382451-84-4 4-[6-bromo-2-(hydroxymethyl)-8-(isobutylamino)imidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylbenzamide 
• 1382451-52-6 N-cyclopropyl-4-[2-(hydroxymethyl)-8-(isobutylamino)-6-phenylimidazo[1,2-a]pyrazin-3-yl]benzamide 
• 1382451-56-0 N-cyclopropyl-4-[2-(fluoromethyl)-8-(isobutylamino)-6-phenylimidazo[1,2-a]pyrazin-3-yl]benzamide 
• 1382451-89-9 N-cyclopropyl-4-{2-formyl-8-[(2-methylpropyl)amino]-6-phenylimidazo[1,2-a]pyrazin-3-yl}benzamide 
• 1382451-59-3 methyl 3-[4-(cyclopropylcarbamoyl)phenyl]-8-[(2-methylpropyl)amino]-6-phenylimidazo[1,2-a]pyrazine-2-carboxylate 
• 1382451-93-5 N-cyclopropyl-4-[2-(hydrazinocarbonyl)-8-(isobutylamino)6-phenylimidazo[1,2-a]pyrazin-3-yl]benzamide 
• 1382451-98-0 3-[4-(cyclopropylcarbamoyl)phenyl]-8-(isobutylamino)-6-phenylimidazo[1,2-a]pyrazine-2-carbonyl azide 
• 1382451-63-9 4-[2-amino-8-(isobutylamino)-6-phenylimidazo[1,2-a]pyrazin-3-yl]-N-cyclopropylbenzamide 
• 87597-32-8 SC 8 

Relevant academic research and scientific papers

DUAL KINASE-BROMODOMAIN INHIBITORS

Provided herein are compounds of Formula (I) that are dual inhibitors of kinases and bromo-domain proteins. The disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, particularly, the treatment of multiple myeloma cancers, and to related uses.

2, 6, 8 - Polysubstituted imidazo [1, 2 - a] pyrazine and synthesis method and application thereof

The invention discloses I, 2 and 6 polysubstituted imidazo [8 - 1] pyrazine of formula (2 - a) or a pharmaceutically acceptable salt thereof. The invention also discloses application of the 2, 6 and 8 - polysubstituted imidazo [1, 2 - a] pyrazine or pharmaceutically acceptable salts thereof as TYK2 inhibitors in preparation of drugs for preventing and treating tumor or inflammation diseases. The invention also provides a synthetic method of the 2, 6, 8 - polysubstituted imidazo [1, 2 - a] pyrazine or a pharmaceutically acceptable salt thereof.

6-THIO-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS

The present invention relates to substituted imidazopyrazine compounds of general formula (I): (I) in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for prep

SUBSTITUTED 6-IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS

The present invention relates to substituted imidazopyrazine compounds of general formula (I), in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparin

2-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS

The present invention relates to substituted imidazopyrizine compounds of general formual (I): in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

6-THIO-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS

The present invention relates to substituted imidazopyrazine compounds of general formula (I) : (I) in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for pre

SUBSTITUTED 6-IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS

The present invention relates to substituted imidazopyrazine compounds of general formula (I), in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparin

6-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS

The present invention relates to substituted imidazopyrazine compounds of general formula (I): in which R1, R2, R3, R4 and R5 are as defined in the claims, to methods of and intermediates for preparin

Synthesis of imidazo[1,2-a]pyrazine derivatives with uterine-relaxing, antibronchospastic, and cardiac-stimulating properties

A series of imidazo[1,2-a]pyrazine derivatives was synthesized by condensation of α-halogenocarbonyl compounds and aminopyrazines. Various compounds resulted from competitive reactions or reagent isomerization and demonstrated in vitro uterine-relaxing and in vivo antibronchospastic activities. On isolated atria, 5-bromoimidazo[1,2-a]pyrazine showed positive chronotropic and inotropic properties; the latter was associated with an increase in the cyclic AMP tissue concentration. Potentiation of the isoproterenol positive inotropic effect of 5-bromoimidazo[1,2-a]pyrazine and the lack of blockade of the 5-bromoimidazo[1,2-a]pyrazine positive inotropic effect by propranolol suggested phosphodiesterase-inhibiting properties.